Laurion Capital Management LP Buys New Stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Laurion Capital Management LP acquired a new stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 2,457,189 shares of the company's stock, valued at approximately $16,611,000. Laurion Capital Management LP owned approximately 0.63% of Recursion Pharmaceuticals at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. Ensign Peak Advisors Inc lifted its position in shares of Recursion Pharmaceuticals by 0.3% in the 4th quarter. Ensign Peak Advisors Inc now owns 410,286 shares of the company's stock worth $2,774,000 after purchasing an additional 1,300 shares during the period. Fullcircle Wealth LLC bought a new stake in Recursion Pharmaceuticals during the 4th quarter valued at $109,000. Deutsche Bank AG increased its holdings in shares of Recursion Pharmaceuticals by 53.6% in the 4th quarter. Deutsche Bank AG now owns 217,723 shares of the company's stock valued at $1,472,000 after acquiring an additional 75,994 shares during the period. Casdin Capital LLC purchased a new stake in shares of Recursion Pharmaceuticals during the fourth quarter valued at about $1,118,000. Finally, Cetera Investment Advisers grew its position in shares of Recursion Pharmaceuticals by 28.6% in the 4th quarter. Cetera Investment Advisers now owns 61,833 shares of the company's stock worth $418,000 after buying an additional 13,751 shares during the last quarter. 89.06% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on RXRX shares. Morgan Stanley lowered their target price on shares of Recursion Pharmaceuticals from $10.00 to $8.00 and set an "equal weight" rating for the company in a research note on Thursday, April 10th. Cowen reiterated a "hold" rating on shares of Recursion Pharmaceuticals in a research note on Friday, February 28th. Leerink Partners cut their price objective on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating on the stock in a report on Friday, February 28th. Finally, Needham & Company LLC lowered their target price on shares of Recursion Pharmaceuticals from $11.00 to $8.00 and set a "buy" rating for the company in a research note on Tuesday, May 6th. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $7.60.

Recursion Pharmaceuticals Stock Performance

RXRX traded down $0.20 during trading on Wednesday, reaching $4.31. 22,256,994 shares of the company's stock were exchanged, compared to its average volume of 13,043,311. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35. Recursion Pharmaceuticals, Inc. has a 1 year low of $3.79 and a 1 year high of $12.36. The company's fifty day simple moving average is $5.41 and its 200-day simple moving average is $6.62. The stock has a market capitalization of $1.73 billion, a P/E ratio of -2.82 and a beta of 0.99.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last issued its earnings results on Monday, May 5th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.06). The business had revenue of $14.75 million for the quarter, compared to analysts' expectations of $18.12 million. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The company's revenue for the quarter was up 7.2% on a year-over-year basis. During the same period last year, the business earned ($0.39) EPS. As a group, research analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.